Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

NCT04584255 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Stage I Breast Cancer
Stage II Breast Cancer
Stage III Breast Cancer
Breast Cancer
HER2-negative Breast Cancer
Germline BRCA1 Gene Mutation
Germline BRCA2 Gene Mutation
Deleterious PALB2 Gene Mutation

Interventions

DRUG: Niraparib
DRUG: Dostarlimab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]